Search Results
86 items found for "Ji'ou Gu"
- N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 ...
October 2022 N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of interaction "Background and purpose: To fully elucidate the regulatory role of the GLP-2 system in the gut
- Community guidelines for GPCR ligand bias: IUPHAR review 32
Here, we provide guidelines and terminology for any scientists to design and report ligand bias experiments The guidelines will aid consistency and clarity, as the basic receptor research and drug discovery communities analytical methods are still evolving and should benefit from and contribute to the implementation of the guidelines
- Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota..
September 2022 Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism , microbiota, and T cell-induced inflammation "Gut intraepithelial lymphocytes (IELs) are thought to Here, we show that the gut IEL GLP-1 receptor (GLP-1R) is not required for enteroendocrine L cell GLP Instead, the gut IEL GLP-1R is essential for the full effects of GLP-1RAs on gut microbiota. Such effects are mediated by the suppression of gut IEL effector functions linked to the dampening of
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
August 2022 "Abstract The β3 -adrenergic receptor (β3 -AR) is found in several tissues such as adipose tissue and urinary bladder. It is a therapeutic target because it plays a role in thermogenesis, lipolysis, and bladder relaxation. Two β3 -AR agonists are used clinically: mirabegron 1 and vibegron 2, which are indicated for overactive bladder syndrome. However, these drugs show adverse effects, including increased blood pressure in mirabegron patients. Hence, new β3 -AR agonists are needed as starting points for drug development. Previous pharmacophore modeling studies of the β3 -AR did not involve experimental in vitro validation. Therefore, this study aimed to conduct prospective virtual screening and confirm the biological activity of virtual hits. Ligand-based pharmacophore modeling was performed since no 3D structure of human β3 -AR is yet available. A dataset consisting of β3 -AR agonists was prepared to build and validate the pharmacophore models. The best model was employed for prospective virtual screening, followed by physicochemical property filtering and a docking evaluation. To confirm the activity of the virtual hits, an in vitro assay was conducted, measuring cAMP levels at the cloned β3 -AR. Out of 35 tested compounds, 4 compounds were active in CHO-K1 cells expressing the human β3 -AR, and 8 compounds were active in CHO-K1 cells expressing the mouse β3 -AR." Read more at the source #DrGPCR #GPCR #IndustryNews
- ShouTi Pharma CEO Dr. Raymond Stevens was interviewed by Moira Gunn of the NPR TechNation podcast
April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Reflections on My PhD Journey: Lessons Learned
My experience has been no different, filled with valuable lessons that I hope will inspire and guide Supervisors not only guide your research but also shape your academic and professional growth.
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
discriminating the endocytic effects of opioid agonist drugs GPCRs in Oncology and Immunology GPR56: GPCR as a guardian
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
This data can guide the modification of the chemical structure of the lead compounds to improve potency This can guide the development of more personalised therapies tailored to the genetic makeup of individual
- Class B1 GPCR Dimerization: Unveiling Its Role in Receptor Function and Signaling
Gusach, A., J. García-Nafría, and C.G. Guo, W., et al., Crosstalk in G protein-coupled receptors: Changes at the transmembrane homodimer interface
- All Aboard the GPCR Express: Your Weekly Update is here! Oct 14-20, 2024
Gunnar Schulte for his excellent work on International Union of Basic and Clinical Pharmacology CXV: Seize the chance to enhance your understanding and expertise in pharmacology under the guidance of the
- GPCR Updates: Celebrating Breakthroughs, New Course Launches Soon, and Exclusive Discounts! | Aug 26 - Sep 1, 2024
Lukas Grätz , Jan Voss , and Gunnar Schulte , for their study on Class-Wide Analysis of Frizzled-Dishevelled
- Decoding GPCR Function: The Role of Mutagenesis in Rational Drug Discovery
Kosar et al. (2024) addressed this question by using the role of the Trp258 6.48 residue to guide and
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
manipulates neuroactive signals and may onset metabolic disturbances GPCR Binders, Drugs, and more Gut
- Unlocking the Future of Medicine: Advancements in GPCR Research
Conformational dynamics underlying atypical chemokine receptor 3 activation Michael Trogdon, J Silvio Gutkind in pre-clinical retinopathy models Reviews, GPCRs, and more Lessons from the physiological role of guanosine continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
- Exploring the Breakthroughs in GPCR Research
Mikel Garcia-Marcos for their work on Get ready to sharpen your tools:A short guide to heterotrimeric phosphorylation-dependent and independent desensitization mechanisms Get ready to sharpen your tools:A short guide
- 📰 GPCR Weekly News, July 1 to 7, 2024
Gunnar Schulte for his study on the International Union of Basic and Clinical Pharmacology.
- 📰 GPCR Weekly News, June 17 to 23, 2024
Persistent Contextual Memory Engram β-arrestins are scaffolding proteins required for Shh-mediated axon guidance
- Do You Believe AI Could Accelerate Drug Discovery?
AlphaFold2 structures guide prospective ligand discovery.
- 📰 GPCR Weekly News, June 10 to 16, 2024
Witness the passion and excitement of our guests as you catch up on missed episodes.
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
In 2017, Gupte et al. introduced GPCR priming, which posits that non-cognate G proteins can enhance the Gupte et al. utilized a systematic protein affinity strength modulation (SPASM) technique to show that Gupte, T.M., et al., Priming GPCR signaling through the synergistic effect of two G proteins.
- 📰 GPCR Weekly News, June 3 to June 9, 2024
Zhan-Guo Gao, Mansour Haddad, and Kenneth A Jacobson for their work on A2B adenosine receptor signaling
- Adhesion GPCR Consortium Newsletter - May 2024
This will greatly impact not only the way we understand how aGPCR works but might also provide a guide
- 📰 GPCR Weekly News, May 13 to 19, 2024
signaling Jiankun Lyu, Brian Shoichet, Bryan Roth, et al. for their research on AlphaFold2 structures guide Partial Activation of the Prototypic G Protein-Coupled Adenosine A2A Receptor AlphaFold2 structures guide
- 📰 GPCR Weekly News, May 6 to 12, 2024
Chakit Arora, J Silvio Gutkind, and Francesco Raimondi for their work on The landscape of cancer-rewired
- 📰 GPCR Weekly News, April 22 to 28, 2024
in models of autism spectrum disorders Systematic characterization of multi-omics landscape between gut
- 📰 GPCR Weekly News, April 8 to 14, 2024
Screening of a Chemically Diverse "Superscaffold" Library Enables Ligand Discovery for a Key GPCR Target Gunnar
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
receptor in 1984 (Cerione et al. 1984), where reconstitution of purified β2-adrenergic receptors from guinea
- 📰 GPCR Weekly News, March 11 to 17, 2024
Hoare's expert guidance, you will gain invaluable skills in data analysis.